Search clinical trials for: SXC-2023

Total 1598 results

Promentis Pharmaceuticals, Inc.

Completed

Randomized, Double-Blind, Placebo-Controlled, MAD Study to Assess the Safety, Tolerability, and Pharmacokinetics of SXC 2023

Healthy Volunteers

United States
Promentis Pharmaceuticals, Inc.

Completed

A Study in Patients With Trichotillomania (TTM)

Trichotillomania

United States
Promentis Pharmaceuticals, Inc.
Celerion

Completed

Placebo-Controlled Single Dose Study to Evaluate Safety and Pharmacokinetics of SXC-2023 in Healthy Volunteers

Healthy

United States
National Institute on Drug Abuse (NIDA)
Technical Resources International, Inc.; Promentis Pharmaceuticals, Inc.; Altasciences...

Not yet recruiting

SXC-2023 Cocaine Interaction Study

Cocaine Use Disorder

United States
Promentis Pharmaceuticals, Inc.
Baylor College of Medicine; Celerion

Completed

Restoring Cognitive Control (ReCon) in Acute Nicotine Withdrawal

Impulse Control Disorders

United States
Sarang K. Yoon, DO, MOH
Novavax; Westat

Recruiting

The Efficacy of the 2023-2024 Updated COVID-19 Vaccines Against COVID-19 Infection (BEEHIVE)

COVID-19 | SARS CoV 2 Infection | Vaccine-Preventable Diseases | Upper Respiratory Tract Infection | Upper Respiratory Disease

United States
University Medicine Greifswald

Active, not recruiting

Adaptive Immune Response to Seasonal Influenza Vaccination (AIGI) ((AIGI))

Seasonal Influenza Vaccination

Germany
Sanofi Pasteur, a Sanofi Company

Completed

Study With Quadrivalent Recombinant Influenza Vaccine (RIV4) in Participants 9 Through 49 Years of Age.

Influenza Immunization

United States, Denmark, Poland, Spain, Czechia
Novo Nordisk A/S

Completed

First Research Study of the Possible New Medicine NNC0113-2023 in Healthy Men.

Diabetes Mellitus, Type 2

United States
McMaster University
Canadian Institutes of Health Research (CIHR)

Recruiting

Relative Impacts on Preventative Primary Care--a Longitudinal Evaluation of COVID-19:Phase 1 (RIPPLE-C)

Diabetes Mellitus | Chronic Kidney Diseases | Chronic Obstructive Pulmonary Disease | Osteoarthritis | Dementia | Congestive Heart Failure | Depression, Anxiety

Canada
Sanofi Pasteur, a Sanofi Company

Completed

Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively

Healthy Volunteers | Influenza Immunization

United States
Sanofi Pasteur, a Sanofi Company

Completed

Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2020-2021 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively

Healthy Volunteers | Influenza Immunization

United States
National Institute of Allergy and Infectious Diseases...
Johns Hopkins University; PPD

Active, not recruiting

COVID Protection After Transplant-Immunosuppression Reduction (CPAT-ISR)

Liver Transplant Recipients | Kidney Transplant Recipients

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Japanese Adults 60 Years of Age and Older

Healthy Volunteers | Influenza Immunization

Japan
Radboud University Medical Center
GlaxoSmithKline

Completed

Age Differences in Influenza and Herpes Zoster Vaccine Responses (INFLUENZA-SHINGRIX)

Influenza | Herpes Zoster

Netherlands
Centre Hospitalier Universitaire de Saint Etienne

Unknown

Surfactant Replacement Guided by Early Lung Ultrasound Score in Preterm Newborns With Respiratory Distress Syndrome (ECHOSURF)

Preterm Birth

France
NVP Healthcare

Recruiting

To Evaluate the Safety and Efficacy of NVP-2203 Tablet in Patients

Cardiovascular Diseases

Korea, Republic of
AstraZeneca

Recruiting

Continuing Sodium Zirconium Cyclosilicate (SZC) After Discharge Study (CONTINUITY)

Chronic Kidney Disease | Hyperkalaemia

United Kingdom, Spain, Belgium, Italy, Netherlands, France, Germany
NVP Healthcare

Completed

To Evaluate the Safety and the Pharmacokinetics of NVP-2203

Healthy Volunteers

Korea, Republic of
CuraSen Therapeutics, Inc.

Withdrawn

A Study of CST-2032 in Subjects With Cognitive Impairment

Mild Cognitive Impairment (MCI) | Parkinson Disease (PD)
Global Alliance for TB Drug Development

Completed

Study to Evaluate Safety, Tolerability, and the PK Profile of TBI-223 in Healthy Subjects

Tuberculosis | Tuberculosis, Pulmonary

United States
Shanghai Jiao Tong University School of Medicine

Recruiting

Allogeneic Transplantation of Expanded Pancreatic Islet Cells

Brittle Type 1 Diabetes

China
Melior Pharmaceuticals
Bukwang Pharmaceutical, Co., Ltd.

Completed

Adult Subjects With Uncontrolled Type 2 Diabetes

Type 2 Diabetes

United States
Shanghai Jiao Tong University School of Medicine

Recruiting

Autologous Transplantation of Expanded Pancreatic Islet Cells (YD01-2022) in Patients

Diabetes After Total Pancreatectomy

China
Eisai Inc.

Available

Extended Access Program With Lorcaserin For The Treatment of Dravet Syndrome and Other Refractory Epilepsies

Epilepsies, Myoclonic | Drug Resistant Epilepsy
Novo Nordisk A/S

Terminated

A Multi-centre, Open Labelled, Multiple Dosing Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC 0172-2021 Administered Subcutaneously to Healthy Male Subjects and Haemophilia Subjects (explorer™2)

Healthy | Congenital Bleeding Disorder | Haemophilia A

Austria, Spain, United Kingdom, France, Germany
Novo Nordisk A/S

Completed

Investigation of the Pharmacokinetics of NNC172-2021, at Two Different Dose Levels, in Healthy Japanese Subjects

Healthy | Congenital Bleeding Disorder | Haemophilia A | Haemophilia B

United Kingdom
Biotie Therapies Corp.

Completed

BTT-1023 in Rheumatoid Arthritis

Rheumatoid Arthritis

Bulgaria
Kainos Medicine Inc.

Completed

Single Ascending Dose (SAD)/Multiple Ascending Dose(MAD) Safety/Pharmacokinetic (PK) Study of KM-023

Human Immunodeficiency Virus

Korea, Republic of
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Not yet recruiting

Phase I Study of SHR-2022 Injection in the Treatment of Patients With Advanced Malignant Tumors

Advanced Malignant Cancer
Eisai Inc.

Recruiting

A Study of Lorcaserin as Adjunctive Treatment in Participants With Dravet Syndrome (MOMENTUM 1)

Epilepsies, Myoclonic

United States, Canada
Catabasis Pharmaceuticals

Completed

A Single and Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of CAT-2003

Dyslipidemia

United States
Orion Corporation, Orion Pharma
Quotient Clinical

Completed

Impact of Changing the Dosing Regimen on the PK Profile of ODM-203 (KIPEV)

Healthy

United Kingdom
Evofem Inc.
Neothetics, Inc

Terminated

Extension Study to Evaluate the Post-Treatment Safety and Duration of Clinical Effect of LIPO-202

Central Abdominal Bulging
Global Alliance for TB Drug Development

Completed

A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of TBI-223 in Healthy Adults

Tuberculosis | Tuberculosis, Pulmonary

United States
CuraSen Therapeutics, Inc.

Completed

A Study of CST-2032 and CST-107 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's or Alzheimer's Disease

Dementia | Mild Cognitive Impairment

United States, New Zealand
Ono Pharmaceutical Co. Ltd

Completed

A Phase 1 Study of ONO-2020 in Healthy Participants

Healthy Volunteers

United States
Tear Film Innovations, Inc.

Completed

Tear Film Innovations iLux Safety Study

Meibomian Gland Dysfunction | Evaporative Dry Eye

United States
Tear Film Innovations, Inc.

Completed

iLux Treatment for Meibomian Gland Dysfunction (MGD)

Evaporative Dry Eye

United States
Catabasis Pharmaceuticals

Completed

Pilot Study To Assess CAT-2003 in Patients With Chylomicronemia

Hypertriglyceridemia | Hyperlipoproteinemia Type I | Lipoprotein Lipase Deficiency, Familial | Chylomicronemia, Familial

Canada
Catabasis Pharmaceuticals

Completed

Pilot Study To Assess CAT-2003 in Patients With Severe Hypertriglyceridemia

Metabolic Diseases | Dyslipidemias | Lipid Metabolism Disorders | Hyperlipidemias | Hypertriglyceridemia

United States
Ischemix, LLC

Completed

Safety and Efficacy of CMX-2043 for Protection of the Heart and Kidneys in Subjects Undergoing Coronary Angiography (CARIN)

Unstable Angina | Non STEMI
Sanofi Pasteur, a Sanofi Company

Completed

Study of Fluzone® Influenza Virus Vaccines 2012-2013 Formulation Among Adults.

Influenza

United States
University of Calgary
Alberta Innovates Health Solutions; Wave View Imaging

Not yet recruiting

Measuring Electrical Properties of Breast Tissues

Healthy | Breast
The University of Hong Kong

Not yet recruiting

Adjunctive Effect of Acupuncture for Advanced Cancer Patients With Palliative Care: a Three-arm Randomized Trial

Advanced Cancer
ModernaTX, Inc.

Active, not recruiting

An Observational Study of Moderna COVID-19 Bivalent Vaccines (Original and Omicron BA.4/BA.5) and 2023 Updated mRNA COVID-19 Vaccines (XBB.1.5)

COVID-19

United States
Tear Film Innovations, Inc.

Completed

Comparison Between iLux™ and LipiFlow® in the Treatment of Meibomian Gland Dysfunction

Meibomian Gland Dysfunction

United States
Novatim Immune Therapeutics (Zhejiang) Co., Ltd.

Recruiting

A Study of KQ-2003 CAR-T Cell Therapy for Patients With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

China
Orion Corporation, Orion Pharma

Completed

Safety and Tolerability of ODM-203 in Subjects With Advanced Solid Tumours (KIDES-203)

Solid Tumours

France, Finland, Spain, Italy, Denmark, United Kingdom
Devalingam Mahalingam
GenSpera, Inc.

No longer available

Continued Administration of G-202 for One Patient With Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma

Search clinical trials for: SXC-2023

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in India

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations